NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03789604,A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03789604,,ACTIVE_NOT_RECRUITING,"This is a multi-center, randomized, double-blind, phase III study to evaluate the efficacy and safety of CS1001 in combination with platinum-containing chemotherapy versus placebo in combination with chemotherapy in first-line treatment-naive subjects with stage IV non-small cell lung cancer (NSCLC).",NO,Non Small Cell Lung Cancer,BIOLOGICAL: CS1001 monoclonal antibody|BIOLOGICAL: CS1001 placebo,"Progression-free survival (PFS) in all subjects evaluated by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, up to approximately 5 years","Overall Survival (OS), OS defined as the time from randomization to all-cause death., up to approximately 7 years|PFS assessed by BICR, PFS defined as the time from randomization to the first occurrence of disease progression or all-cause death (whichever occurs first), as determined by the BICR according to RECIST v1.1, up to approximately 5 years|PFS in subgroup of participants with PD-L1 Expression≥1%, as determined by the investigator, PFS after randomization as determined by the investigator according to RECIST v1.1 in the subgroup of patients with PD-L1 expression ≥1% defined by the SP263 immunohistochemistry (IHC) assay., up to approximately 5 years|Objective Response Rate (ORR) assessed by the investigator according to RECIST v1.1, ORR, defined as the proportion of patients with a complete response (CR) or partial response (PR) on two consecutive occasions \>=4 weeks apart, as determined by the investigator according to RECIST v1.1., up to approximately 5 years|Duration of response (DOR) assessed by the investigator according to RECIST v1.1, DOR defined as the time between the date of the earliest qualifying response and the date of progressive disease or all-cause death, whichever occurs first, as determined by the investigator according to RECIST v1.1., up to approximately 5 years|Safety and tolerability of CS1001 or placebo in combination with platinum-based chemotherapy, up to approximately 5 years|Pharmacokinetics (PK) and immunogenecity of CS1001, up to approximately 5 years|Efficacy of CS1001 monotherapy in subjects cross over to receive CS1001 who experienced progressive disease after assigned to the placebo group in the double-blind phase (CS1001 or placebo in combination with chemotherapy), up to approximately 5 years",,CStone Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,479,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CS1001-302,2018-12-13,2023-05-15,2025-06-30,2018-12-28,,2024-08-09,"Shanghai Pulmonary Hospital, Shanghai, Shanghai, China",
